BIOMARKERS FOR PREDICTING MAJOR ADVERSE EVENTS
1 Assignment
0 Petitions
Accused Products
Abstract
Provided herein are diagnostic markers and uses thereof for predicting if a subject is at risk of a major adverse event. In particular, one aspect provided herein relates to methods to determine if a subject is at risk of having a major adverse effect by measuring at least 2, or at least 3 of the biomarkers beta 2 microglobulin, c-reactive protein and cystatin C.
-
Citations
51 Claims
-
1-30. -30. (canceled)
- 31. A method of identifying a subject at risk of a major adverse event, the method comprising detecting in a biological sample taken from the subject presenting a symptom of an acute cardiac event, or BMI of 25-30 or greater than 30, for the level of at least three biomarkers selected from beta-2-microglobulin, c-reactive protein (CRP) and cystatin C, wherein combination of the levels of beta-2-microglobulin, c-reactive protein (CRP) and cystatin C equal to, or above a threshold reference level for each of beta-2-microglobulin, c-reactive protein (CRP) and cystatin C indicates that the subject is at risk of a major adverse event.
-
32. A method of identifying a subject suitable for treatment to prevent the occurrence of a major adverse event, the method comprising detecting in a biological sample taken from the subject presenting a symptom of an acute cardiac event, or BMI of 25-30 or greater than 30, for the level of at least three biomarkers selected from beta-2-microglobulin, c-reactive protein (CRP) and cystatin C, wherein the combination of the levels of beta-2-microglobulin, c-reactive protein (CRP) and cystatin C above threshold reference levels for each beta-2-microglobulin, c-reactive protein (CRP) and cystatin C indicates that the subject should undergo treatment to reduce the incidence of a major adverse event.
-
43. (canceled)
- 44. A method for treating a human subject with a risk of a major adverse event, comprising administering a treatment or therapy to prevent the occurrence of a major adverse event to a human subject who is determined to have a level of beta-2-microglobulin, c-reactive protein (CRP) and cystatin C equal to, or above a reference threshold level for each biomarker.
Specification